Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 2, 53100 Siena, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, L.go P. Daneo 3, 16132 Genova, Italy.
Cells. 2023 Dec 26;13(1):54. doi: 10.3390/cells13010054.
This review analyzes the role of TNF-α and its increase in biological fluids in mild cognitive impairment, and Alzheimer's disease (AD). The potential inhibition of TNF-α with pharmacological strategies paves the way for preventing AD and improving cognitive function in people at risk for dementia. We conducted a narrative review to characterize the evidence in relation to the involvement of TNF-α in AD and its possible therapeutic inhibition. Several studies report that patients with RA and systemic inflammatory diseases treated with TNF-α blocking agents reduce the probability of emerging dementia compared with the general population. Animal model studies also showed interesting results and are discussed. An increasing amount of basic scientific data and clinical studies underscore the importance of inflammatory processes and subsequent glial activation in the pathogenesis of AD. TNF-α targeted therapy is a biologically plausible approach for cognition preservation and further trials are necessary to investigate the potential benefits of therapy in populations at risk of developing AD.
本综述分析了 TNF-α 及其在轻度认知障碍和阿尔茨海默病(AD)生物体液中的增加的作用。通过药理学策略抑制 TNF-α 为预防 AD 和改善痴呆风险人群的认知功能铺平了道路。我们进行了叙述性综述,以描述与 TNF-α 参与 AD 及其可能的治疗性抑制相关的证据。几项研究报告称,与普通人群相比,接受 TNF-α 阻断剂治疗的类风湿关节炎和全身性炎症性疾病患者出现痴呆的概率降低。动物模型研究也显示出有趣的结果,并进行了讨论。越来越多的基础科学数据和临床研究强调了炎症过程和随后的神经胶质激活在 AD 发病机制中的重要性。针对 TNF-α 的治疗是一种具有生物学意义的保留认知的方法,需要进一步的试验来研究该疗法在有发生 AD 风险的人群中的潜在益处。